Enzymatic property analysis of p53R2 subunit of human ribonucleotide reductase

Yun Yen, Bernard Chu, Christina Yen, Jennifer Shih, Bingsen Zhou

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

p53R2 is a newly identified subunit of ribonucleotide reductase (RR) and plays a crucial role in supplying precursors for DNA repair in a p53-dependent manner. In our current work, all three human RR subunit proteins (p53R2, hRRM2, and hRRM1) were prokaryotically expressed and highly purified. Using an in vitro [3H] CDP reduction assay, the activity of RR reconstituted with either p53R2 or hRRM2 was found to be time, concentration, and hRRM1 dependent. The kinetic activity of p53R2-containing RR was about 20%-50% lower than that of hRRM2-containing RR. Using a synthetic heptapeptide to inhibit RR activity, it was shown that p53R2 bound to hRRM1 through the same C-terminal heptapeptide as hRRM2. However, hRRM2 had a 4.76-fold higher binding affinity for hRRM1 than p53R2, which may explain the reduced RR activity of p53R2 relative to hRRM2. Interestingly, p53R2 was 158-fold more susceptible to the iron chelator deferoxamine mesylate than hRRM2 although the iron content of the two proteins determined by atomic absorption spectrometry was almost the same. Conversely, p53R2 was 2.50-fold less sensitive than hRRM2 to the radical scavenger hydroxyurea, though EPR spectra of the tyrosyl radical in the two proteins were similar. Triapine, a new RR inhibitor, was equally potent for p53R2 and hRRM2. These inhibition studies showed that the iron center and tyrosyl radical are involved in RR activity for both p53R2 and hRRM2. The differences in susceptibility to RR inhibitors between p53R2 and hRRM2 may lead to a new direction in drug design for human cancer treatment.

Original languageEnglish
Pages (from-to)235-247
Number of pages13
JournalAdvances in Enzyme Regulation
Volume46
Issue number1
DOIs
Publication statusPublished - Sep 4 2006
Externally publishedYes

Fingerprint

Ribonucleotide Reductases
Iron
Cytidine Diphosphate
Deferoxamine
Hydroxyurea
Drug Design
Protein Subunits
Chelating Agents
DNA Repair
Spectrum Analysis
Proteins

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Enzymatic property analysis of p53R2 subunit of human ribonucleotide reductase. / Yen, Yun; Chu, Bernard; Yen, Christina; Shih, Jennifer; Zhou, Bingsen.

In: Advances in Enzyme Regulation, Vol. 46, No. 1, 04.09.2006, p. 235-247.

Research output: Contribution to journalArticle

Yen, Yun ; Chu, Bernard ; Yen, Christina ; Shih, Jennifer ; Zhou, Bingsen. / Enzymatic property analysis of p53R2 subunit of human ribonucleotide reductase. In: Advances in Enzyme Regulation. 2006 ; Vol. 46, No. 1. pp. 235-247.
@article{8cdf4f43d9484319947e6dfbf124e53a,
title = "Enzymatic property analysis of p53R2 subunit of human ribonucleotide reductase",
abstract = "p53R2 is a newly identified subunit of ribonucleotide reductase (RR) and plays a crucial role in supplying precursors for DNA repair in a p53-dependent manner. In our current work, all three human RR subunit proteins (p53R2, hRRM2, and hRRM1) were prokaryotically expressed and highly purified. Using an in vitro [3H] CDP reduction assay, the activity of RR reconstituted with either p53R2 or hRRM2 was found to be time, concentration, and hRRM1 dependent. The kinetic activity of p53R2-containing RR was about 20{\%}-50{\%} lower than that of hRRM2-containing RR. Using a synthetic heptapeptide to inhibit RR activity, it was shown that p53R2 bound to hRRM1 through the same C-terminal heptapeptide as hRRM2. However, hRRM2 had a 4.76-fold higher binding affinity for hRRM1 than p53R2, which may explain the reduced RR activity of p53R2 relative to hRRM2. Interestingly, p53R2 was 158-fold more susceptible to the iron chelator deferoxamine mesylate than hRRM2 although the iron content of the two proteins determined by atomic absorption spectrometry was almost the same. Conversely, p53R2 was 2.50-fold less sensitive than hRRM2 to the radical scavenger hydroxyurea, though EPR spectra of the tyrosyl radical in the two proteins were similar. Triapine, a new RR inhibitor, was equally potent for p53R2 and hRRM2. These inhibition studies showed that the iron center and tyrosyl radical are involved in RR activity for both p53R2 and hRRM2. The differences in susceptibility to RR inhibitors between p53R2 and hRRM2 may lead to a new direction in drug design for human cancer treatment.",
author = "Yun Yen and Bernard Chu and Christina Yen and Jennifer Shih and Bingsen Zhou",
year = "2006",
month = "9",
day = "4",
doi = "10.1016/j.advenzreg.2006.01.016",
language = "English",
volume = "46",
pages = "235--247",
journal = "Advances in Biological Regulation",
issn = "2212-4926",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Enzymatic property analysis of p53R2 subunit of human ribonucleotide reductase

AU - Yen, Yun

AU - Chu, Bernard

AU - Yen, Christina

AU - Shih, Jennifer

AU - Zhou, Bingsen

PY - 2006/9/4

Y1 - 2006/9/4

N2 - p53R2 is a newly identified subunit of ribonucleotide reductase (RR) and plays a crucial role in supplying precursors for DNA repair in a p53-dependent manner. In our current work, all three human RR subunit proteins (p53R2, hRRM2, and hRRM1) were prokaryotically expressed and highly purified. Using an in vitro [3H] CDP reduction assay, the activity of RR reconstituted with either p53R2 or hRRM2 was found to be time, concentration, and hRRM1 dependent. The kinetic activity of p53R2-containing RR was about 20%-50% lower than that of hRRM2-containing RR. Using a synthetic heptapeptide to inhibit RR activity, it was shown that p53R2 bound to hRRM1 through the same C-terminal heptapeptide as hRRM2. However, hRRM2 had a 4.76-fold higher binding affinity for hRRM1 than p53R2, which may explain the reduced RR activity of p53R2 relative to hRRM2. Interestingly, p53R2 was 158-fold more susceptible to the iron chelator deferoxamine mesylate than hRRM2 although the iron content of the two proteins determined by atomic absorption spectrometry was almost the same. Conversely, p53R2 was 2.50-fold less sensitive than hRRM2 to the radical scavenger hydroxyurea, though EPR spectra of the tyrosyl radical in the two proteins were similar. Triapine, a new RR inhibitor, was equally potent for p53R2 and hRRM2. These inhibition studies showed that the iron center and tyrosyl radical are involved in RR activity for both p53R2 and hRRM2. The differences in susceptibility to RR inhibitors between p53R2 and hRRM2 may lead to a new direction in drug design for human cancer treatment.

AB - p53R2 is a newly identified subunit of ribonucleotide reductase (RR) and plays a crucial role in supplying precursors for DNA repair in a p53-dependent manner. In our current work, all three human RR subunit proteins (p53R2, hRRM2, and hRRM1) were prokaryotically expressed and highly purified. Using an in vitro [3H] CDP reduction assay, the activity of RR reconstituted with either p53R2 or hRRM2 was found to be time, concentration, and hRRM1 dependent. The kinetic activity of p53R2-containing RR was about 20%-50% lower than that of hRRM2-containing RR. Using a synthetic heptapeptide to inhibit RR activity, it was shown that p53R2 bound to hRRM1 through the same C-terminal heptapeptide as hRRM2. However, hRRM2 had a 4.76-fold higher binding affinity for hRRM1 than p53R2, which may explain the reduced RR activity of p53R2 relative to hRRM2. Interestingly, p53R2 was 158-fold more susceptible to the iron chelator deferoxamine mesylate than hRRM2 although the iron content of the two proteins determined by atomic absorption spectrometry was almost the same. Conversely, p53R2 was 2.50-fold less sensitive than hRRM2 to the radical scavenger hydroxyurea, though EPR spectra of the tyrosyl radical in the two proteins were similar. Triapine, a new RR inhibitor, was equally potent for p53R2 and hRRM2. These inhibition studies showed that the iron center and tyrosyl radical are involved in RR activity for both p53R2 and hRRM2. The differences in susceptibility to RR inhibitors between p53R2 and hRRM2 may lead to a new direction in drug design for human cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=33748085352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748085352&partnerID=8YFLogxK

U2 - 10.1016/j.advenzreg.2006.01.016

DO - 10.1016/j.advenzreg.2006.01.016

M3 - Article

C2 - 16846634

AN - SCOPUS:33748085352

VL - 46

SP - 235

EP - 247

JO - Advances in Biological Regulation

JF - Advances in Biological Regulation

SN - 2212-4926

IS - 1

ER -